Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cold exposure melt away liver fat?

NCT ID NCT07821749

Symptom relief Sponsor: Renmin Hospital of Wuhan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers test whether repeated cold exposure using a water-perfused cooling suit can reduce liver fat and improve liver health in adults with metabolic dysfunction-associated steatohepatitis (MASH). Eleven participants wear the suit for about two hours daily over three months. The study measures changes in liver fat by MRI, liver enzymes, cholesterol, and body weight, and tracks safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a water-perfused cooling suit that lowers body temperature through circulating cold water
What this could lead to
If cold exposure helps, it could offer a drug-free way to reduce liver fat and ease liver stress in people with MASH.
What could go wrong
This is a tiny, single-arm study with no control group, so any changes could be due to chance or other factors. Cold exposure can cause discomfort, and people with heart or circulation problems may not tolerate it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

11 people

The number who actually took part.

Started

Jul 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Adults aged 18 to 70 years. 2. Diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). 3. Able to understand and provide written informed consent. 4. Willing to comply with the study intervention and follow-up assessments. Exclusion Criteria: * 1\. Significant alcohol consumption or other causes of chronic liver disease. 2. Severe cardiovascular, respiratory, renal, or other systemic diseases. 3. Conditions contraindicating cold exposure. 4. Pregnancy or breastfeeding. 5. Use of medications or participation in other clinical studies that may significantly affect metabolic outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction associated steatohepatitis (MASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction associated steatohepatitis (MASH)

Contacts and locations

Locations

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.